

In reply please
refer to:

WCO/INO/MAL/RFQ 140-2019

Originator:

Procurement Unit

Interpretation Services & Devices
Jakarta
Indonesia
Attn: Sales Representative

Jakarta, 26 August 2019

Subject: Request for Quotation: Interpreter Services for Workshop JMPR Indonesia 2019 – Jakarta

CLOSING DATE: Friday 30th August 2019, 10:00 hours

As part of its work, the World Health Organization, Country Office in Indonesia undertakes jointly with Member States and other specialized UN Agencies, a variety of health projects for which equipment and supplies are provided free of charge by the Organization. Purchases of such material are non-commercial and international in character, as the products in question are for use in health programmes mainly in Indonesia or in the offices of the Organization itself.

Please send us your best offer in IDR, as per the following details:

No.	Description	Qty	Unit	Price per Unit (IDR)	Total Cost (IDR)
1	Interpreter Services (Bahasa Indonesia – English) for workshop preparation joint malaria review in Jakarta on 9 - 10 September 2019 and de-briefing workshop in Jakarta on 19 - 20 September 2019	1	Person		
2	Interpreter devices	30	Unit		
3	Transportation Cost in Jakarta	1	Person		

Note:

- Price quoted is in **IDR currency only** with **DAP Jakarta**
- Prices quoted should be Customs Duty free as WHO is exempt from all statutory levies, taxes and duties.
- Terms and conditions attached.
- Please send us your quotation by email to **tandjungm@who.int** and copy **seinobids@who.int** with ref no. **WCO/MAL/RFQ/140-2019**



For WHO Representative, Indonesia

75



GENERAL TERMS AND CONDITIONS

General Terms and Conditions

1. ACKNOWLEDGEMENT COPY

Acceptance of a Purchase Order shall form a binding contract with the Vendor signing and returning the acknowledgement copy or by the timely delivery of the goods specified. The contract between the parties is subject only to the terms and conditions detailed here below. Any contractual terms and conditions of the contractor, whether included in the offer, invoices or any other document, are hereby excluded. In the event this purchase order contains any provisions, which are contrary to the provisions of the contractor's offer, the provisions of this purchase order shall take precedence.

2. DELIVERY DATE

Delivery Date to be understood as the time the goods have to be available at the location indicated under Delivery Terms.

3. PAYMENT TERMS

- (a) World Health Organisation further referred to as WHO shall, on fulfilment of the Delivery Terms, unless otherwise specified in the Purchase Order, make payment within 30 days of receipt of the Vendor's invoice for the goods and copies of the customary Shipping documents specified in the contract.
- (b) Payment against the invoice referred to above will reflect any discount shown under the payment terms provided payment is made within the period shown in the payment terms of the contract.
- (c) Unless authorized by WHO, a separate invoice must be submitted in respect of each Purchase Order. Each invoice shall indicate the identification number of the corresponding Purchase Order.
- (d) The prices shown in the Purchase Order may not be increased except by express written agreement of WHO.
- (e) Inspection prior to shipment does not relieve the Vendor from his contractual obligations.
- (f) WHO shall have a reasonable time after delivery of the goods to inspect them and to reject and refuse acceptance of goods not conforming to the Purchase order; payment for goods pursuant to the Purchase Order shall not be deemed an acceptance of the goods.
- (g) In case of goods which require installation 90% payments will be made initially as per WHO standard term and the balance 10% will be paid on receipt of satisfactory installation/commissioning/delivery receipt from the end-user.
- (h) WHO does not make "advance payment", nor does it establish a letter of credit.

4. TAX EXEMPTION

- (a) Section 7 of the Convention on the Privileges and Immunities of the United Nations provides, inter alia, that the UN, including its Subsidiary organs, as well as specialized agencies, is exempt from all direct taxes and is exempt from customs duties in respect of articles imported or exported for its official use. Accordingly, the Vendor authorizes

WHO to deduct from the Vendor's invoice any amount representing such taxes or duties charged by the Vendor to WHO. Payment of such corrected invoiced amount shall constitute full payment by WHO. In the event any taxing authority refuses to recognize the exemption status from such taxes, the Vendor shall immediately consult with WHO to determine a mutually acceptable procedure.

- (b) Items listed in the Schedule to the Central Excise Tariff Act, 1995 (5 of 1986), when supplied to the United Nations or an International Organization for their official use, or supplied to the projects financed by the said United Nations or an International Organization shall be exempt from payment of excise duty in pursuance to Ministry of Finance Notification No. 108/95-CENTRAL EXCISE of August 28 1995. Accordingly, the prices quoted should be exclusive of excise duty. Similar exemptions are applicable for sales tax and octroi also. Necessary exemption certificates to this effect shall be provided at appropriate time.

5. EXPORT LICENCE

The contract is subject to the obtaining of any export licence or other governmental authorization which may be necessary. It will be the responsibility of the firm to obtain such licence or authorization, but the World Health Organization will do everything in its power to assist. In the event of refusal thereof, the contract will be annulled and all claims between the parties automatically waived. For export licence application and Exchange Control purposes, the source of funds or type of account from which payment for this order will be made is named overleaf.

6. RISK OF LOSS

Risk of loss, injury or destruction to the goods shall be borne by the Vendor until physical delivery of the goods has been completed in accordance with the Purchase Order.

7. FITNESS OF GOODS/PACKING

Vendor warrants that the goods, including adequate packaging, conform to the specifications and are fit for the purposes for which such goods are ordinarily used and for purposes expressly made known to the Vendor by WHO and are free from defects in workmanship and materials. The Vendor also warrants that the goods are contained or packaged adequately to protect the goods.

8. WARRANTY CLAUSE

The Vendor warrants that the use or supply by WHO of the goods offered for sale under the Purchase Order do not infringe any patent, trade-name, or trade-mark. In addition, the Vendor shall pursuant to this warranty indemnify, defend and hold harmless WHO and the United Nations from any actions or claims brought against WHO or the United Nations pertaining to the alleged infringement of a patent, design, trade-name or trade-mark arising from the Purchase Order.

9. FORCE MAJEURE

Neither party to the contract shall be held responsible for delay in the fulfilment thereof due to force majeure, strikes, lock-out, war, civil unrest, or other factors outside its control.

10. RIGHTS OF WHO

In case of failure by the Vendor to perform under the terms and Conditions of the Purchase Order, including but not limited to failure to obtain necessary export licences, or to make delivery of all or part of the goods by the agreed delivery date or dates, WHO may, after giving the Vendor reasonable notice to perform and without prejudice to any other rights or remedies, exercise one or more of the following rights:

- (a) Procure all or part of the goods from other sources, in which event WHO may hold the Vendor responsible for any excess cost occasioned thereby.
- (b) Refuse to accept delivery of all or part of the goods.
- (c) Terminate the Purchase Order.
- (d) In the event the delivery is delayed beyond the period quoted by the supplier, WHO reserves the right to apply a penalty of 2% of the order value for every 30 days of delayed delivery and / or cancel the order.

11. INDEMNIFICATION

The Vendor shall indemnify and save harmless WHO and the Government who receives the items referred to herein from and against all claims, damages, losses, costs and expenses arising out of any injury, sickness or death to persons or any loss of or damage to property, caused by the fault or negligence of the Vendor. WHO shall promptly give notice to the Vendor of any claims, damages, losses, costs and expenses and shall cooperate in a reasonable manner with the Vendor.

12. ASSIGNMENT AND INSOLVENCY

(a) The Vendor shall not assign, transfer, pledge or make other disposition of this Contract or any part thereof, or any of the Vendor's rights, claims or obligations under this Contract except with the prior written consent of the WHO.

(b) Should the Vendor be adjudged bankrupt, or be liquidated or become insolvent, or should the Vendor make an assignment for the benefit of its creditors, or should a Receiver be appointed on account of the insolvency of the Vendor, the WHO may, without prejudice to any other right or remedy it may have under the terms of these conditions, terminate this Contract forthwith. The Vendor shall immediately inform the WHO of the occurrence of any of the above events.

13. USE OF NAME, EMBLEM OR OFFICIAL SEAL OF THE WHO

The Vendor shall not advertise or otherwise make public the fact that it is a Vendor with the WHO, nor shall the Vendor, in any manner whatsoever use the name, emblem or official seal of the WHO, or any abbreviation of the name of the WHO in connection with its business or otherwise.

14. ARBITRATION

Any controversy or claim arising out of or in connection with the Purchase Order or any breach thereof, shall, unless it is settled by Direct negotiation, be settled by the UNCITRAL Arbitration Rules as at present in force. The parties to the Contract shall be bound by any arbitration award rendered as a result of such arbitration as the final adjudication of such controversy or claim.

15. PRIVILEGES AND IMMUNITIES

Nothing in or relating to this Contract shall be deemed a waiver, express or implied, of any of the privileges and

immunities of the United Nations, including its subsidiary organs.

16. GENERAL

- (a) WHO reserves the right to accept or reject any quotation in part or in full without assigning any reason thereof and no correspondence/inquiry is entertained in this respect.
- (b) Normally all bids under <\$70,000 are not opened publicly. Only in the case of large or complex tenders, WHO in its own discretion invites vendors for a public opening at a place/time specified in the solicitation documents.

17. PHARMACEUTICAL PRODUCTS

For pharmaceutical formulations, the standards conformed to IP, BP, USP etc., and the shelf-life at the time of delivery must be specified.

As a matter of principle, the World Health Organization (WHO) applies the WHO Certification Scheme on the quality of products moving in international trade. Therefore, suppliers are requested to provide product certificates issued by the competent drug regulatory authority in the supplier's country (e.g. Drug Controller in the case of Indian suppliers). The certificate(s) should state the (i) the supplier manufacturers in conformity with requirements for Good Manufacturing Practices (GMP) in regularly inspected manufacturing plants, and (ii) the product(s) offered are authorized to be placed on the domestic and/or export market.

18. Quotations must be valid for at least three months and if an order is placed, the price must remain firm until satisfactorily executed.

19. The supplier should provide full description of proposed items and submit product brochures. Vendors may be requested to provide samples of the products.

TERM OF REFERENCE
MID-TERM JOINT REVIEW OF MALARIA PROGRAM, INDONESIA,
9-21 SEPTEMBER 2019 (tentative)

1. PURPOSE

The purpose of this position is to provide technical support to be interpreter for workshop in Joint Malaria Programme Review 2019.

2. BACKGROUND

The number of malaria cases globally has levelled off from 2015–2017. There were an estimated 219 million cases and 435 000 related deaths in 2017. There are 52 moderate to high-burden countries that contributed 60% or more malaria cases worldwide. However, some promising progresses from high burden malaria countries made a positive sign to the achievement of global target. In 2018, the SEA region was carrying the second-highest global burden of morbidity and mortality of malaria, and accounted for 56% of the global burden of Plasmodium vivax. Nearly half of the global at-risk population of malaria live in the SEAR, estimated 1.4 billion people. Malaria is endemic in nine out of 11 countries of the region, India and Indonesia accounted for 68% and 21% of the reported cases and 65% and 16% of malaria deaths, respectively (1).

Indonesia is on track of the achievement of the National Mid Term Development Goal 2015-2019 (Rancangan Pembangunan Jangka Menengah Nasional/RPJMN) for malaria indicator. Of targeted 285 districts/cities, 100% (285 districts/cities) achieved elimination status in 2018 (2). Despite, the number of cases in Indonesia has declined by 47% from 418,439 in 2009 to 222,085 in 2018; the reduction of malaria cases since 2015 was levelled off. It was estimated that 25% of population are living in the risk areas of malaria transmission (2).

In line with World Health Assembly resolution 60.18 year 2007 and Ministerial Declaration at SEA region on malaria elimination for each country, government of Indonesia aim to achieve malaria elimination by 2030. This commitment has been endorsed through Health Minister Decree no 293 Year 2009 (3). Therefore, more efforts

to accelerate these achievements need to be enhanced in order to achieve Indonesia malaria elimination goal by 2030.

Current strategy of MoH to achieve malaria elimination in Indonesia is using sub-national level approach from district to province certification of elimination. The milestones towards malaria elimination by 2030 in Indonesia are (1) by 2025, all 514 districts and cities are succeeded in interrupting local transmission; (2) by 2027, all 34 provinces reached malaria elimination status; (3) by 2029, MoH will apply to WHO for certification of malaria elimination; (4) by 2030, the GoI receives a certificate malaria elimination from WHO (4). The new proposed milestone to achieve malaria elimination in Indonesia is regional islands verification. This regional islands verification will be divided into five regions: (1) Java and Bali Islands will be verified by 2023; (2) Sumatera, Sulawesi and NTB Islands will be verified by 2025; (3) Kalimantan and North Maluku Islands will be verified by 2027; (4) NTT and Maluku Islands will be verified by 2028; (5) Papua and West Papua Islands will be verified by 2029. The new proposed milestones aim to be included in the coming program review.

Malaria program reviews (MPR) are conducted for periodic and collaborative evaluations of national control programs. The objectives of the review are to provide evidences and recommendations to improve operational performance and the delivery of antimalarial interventions in achieving malaria elimination. Program performance will be reviewed to identify achievements of outcomes and impacts, best practices and lesson learnt, critical issues, problems and the causes of the problems. This mid-term review helps countries to assess their strategies and activities with a view to strengthen the program and the systems used to deliver interventions, as well as to identify what is working and what is not and of solutions to challenges or barriers to program implementation. Additionally, the findings and recommendations will be used as reference in the development documents of National Strategic Planning 2020-2024, and Roadmap Malaria Elimination 2030 and Prevention Re-Introduction Plan. Furthermore, this will facilitate planning and resource mobilization for further scaling-up of malaria control services at country level (5).

Indonesia has conducted the last malaria program review in 14-25 November 2016 (after five years from the previous review in 2011). This year, joint malaria program

review is planned in September 2019 (9-21 September 2019). External malaria experts in collaboration with national experts and all related stakeholders (WHO, UNICEF, CDC US, NGOs, etc) will be part of the review team. WHO country office, WHO/HQ, and WHO/SEARO will also take part in the review. All aspects in malaria control/elimination (epidemiology; diagnosis and treatment; vector control and prevention; behaviour change, communication and social mobilization; surveillance, data management and monitoring evaluation; health system and financing, procurement and supply chain management) will be reviewed. In-depth review of the Indonesia Malaria Program recommendations and measures will be proposed to further strengthen the program and to provide guidance on its strategic direction toward the achievement malaria elimination by 2030 (6).

3. OBJECTIVES

General objective:

To provide assist participants of workshop in translating Bahasa Indonesia – English during workshop preparation joint malaria review at 9 – 10 September 2019 and debriefing workshop at 19-20 September 2019 in Jakarta including 30 headphones for participants.

4. EXPECTED OUTPUTS

High quality interpreter during the workshops.

5. Profile of the Ideal Candidate

Qualification:

- Strong background in translation health events.
- Show a clear and mature style of design, demonstrating an understanding of the communication requirements of a UN agency.
- Proven experience of translated health terms and interpreter WHO workshop/events.
- Good understanding of new and evolving technologies and digital platforms;
- Knowledge of standard software packages, including MS Office;
- Working experience in development or humanitarian environment is desirable

6. Payment term and schedule

This application is open for individuals. Estimated contract value: USD 10,000.

Individuals should provide the following:

- CV;
- Letter of application;
- References list;
- Copy of catalogue or samples of work, if available;
- Completed fees/price list based on the work volume/type of services

No	Deliverables	Payment Value in IDR
1	Countersigned Contract (25%)	As per the rule of contract
2	Submission of final report as per the terms of reference & deliverable, and financial statement (75%)	As per the rule of contract